Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Lee

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Immunotherapy|March 10, 2012
Myeloid suppressor cells and immune modulation in lung cancerMinu K Srivastava, Åsa Andersson, Li Zhu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003
Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in miceJay M Lee, Robert E Merritt, Ali Mahtabifard, et al.
Journal of Atrial Fibrillation|December 19, 2017
Atrioesophageal Fistula After Atrial Fibrillation Ablation: A single center seriesHouman Khakpour, Richard J Shemin, Jay M Lee, et al.
Proceedings of the American Thoracic Society|November 20, 2008
Smoking and lung cancer: the role of inflammationTonya Walser, Xiaoyan Cui, Jane Yanagawa, et al.
Translational Cancer Research|May 13, 2024
Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked databaseJay M Lee, Tu My To, Shu Wang, et al.
Expert Opinion on Therapeutic Targets|March 20, 2013
TLR3 agonists and proinflammatory antitumor activitiesSherven Sharma, Li Zhu, Michael Davoodi, et al.
JTCVS Open|April 17, 2023
The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screeningNanruoyi Zhou, John Deng, Claire Faltermeier, et al.
JTO Clinical and Research Reports|November 8, 2021
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLCJay M Lee, Anthony W Kim, Tomasz Marjanski, et al.
American Journal of Clinical Oncology|October 9, 2025
A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United StatesAmy L Cummings, Jesse Sussell, Katherine L Rosettie, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2025
A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancerAmy L Cummings, Jesse Sussell, Katherine L Rosettie, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Immunotherapy|March 10, 2012
Myeloid suppressor cells and immune modulation in lung cancerMinu K Srivastava, Åsa Andersson, Li Zhu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003
Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in miceJay M Lee, Robert E Merritt, Ali Mahtabifard, et al.
Journal of Atrial Fibrillation|December 19, 2017
Atrioesophageal Fistula After Atrial Fibrillation Ablation: A single center seriesHouman Khakpour, Richard J Shemin, Jay M Lee, et al.
Proceedings of the American Thoracic Society|November 20, 2008
Smoking and lung cancer: the role of inflammationTonya Walser, Xiaoyan Cui, Jane Yanagawa, et al.
Translational Cancer Research|May 13, 2024
Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked databaseJay M Lee, Tu My To, Shu Wang, et al.
Expert Opinion on Therapeutic Targets|March 20, 2013
TLR3 agonists and proinflammatory antitumor activitiesSherven Sharma, Li Zhu, Michael Davoodi, et al.
JTCVS Open|April 17, 2023
The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screeningNanruoyi Zhou, John Deng, Claire Faltermeier, et al.
JTO Clinical and Research Reports|November 8, 2021
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLCJay M Lee, Anthony W Kim, Tomasz Marjanski, et al.
American Journal of Clinical Oncology|October 9, 2025
A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United StatesAmy L Cummings, Jesse Sussell, Katherine L Rosettie, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2025
A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancerAmy L Cummings, Jesse Sussell, Katherine L Rosettie, et al.
Pageof 10